University of Texas System

Argenx Bv

Argenx Bvba

Argenx Se

E Sally Ward Ober

Torsten Dreier

Christophe Blanchetot

Peter Ulrichts

Johannes De Haard

Nicolas G H Ongenae

Alan J Schroit

Adi Gazdar

Nicolas Gh Ongenae

Nicolas GH Ongenae

Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.

FcRn antagonists and methods of use

Disclosed are methods of identifying tumor-derived exosomes as an early cancer diagnostic, as well as for staging, assessing progression and assessing therapy of cancer.

Diagnostic test for early stage cancer

FCRN antagonists and methods of use

The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.

Immunoglobulin molecules with improved characteristics

Growing community of inventors

Dallas, TX, United States of America

E Sally Ward Ober